On February 1, 2023 Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), reported that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences (Press release, Merus, FEB 1, 2023, View Source [SID1234626720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks/Oncology Conference: Wednesday, February 8 at 11:20-11:45 a.m. ET
SVB Securities Global Biopharma Conference: Tuesday, February 14 at 3:40-4:10 p.m. ET
Citi’s 2023 Oncology Leadership Summit: Thursday, February 23 at 10:00-11:00 a.m. ET
The webcasts of the presentations will be contemporaneously available on the Investors page of the Company’s website. Archived presentations will also be available there for a limited time after the event.